A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the drug CT-868 on blood sugar control in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 32 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2023-03 · est. completion 2024-04

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05794581 ↗

Description as written by the study sponsor.

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

CT-868 Drug

CT-868
Placebo Drug

Placebo as SC Injection
Victoza also known as Liraglutide Drug

Victoza as active comparator as SC Injection

Main thing measured	To assess area under the curve (AUC) in glucose metabolism during MMTT
Sponsor	Carmot Therapeutics, Inc.
Conditions studied	Type 1 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05794581 ↗